Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Lisa DeFazio Eli"'
Autor:
James J. Harding, Sarina Anne Piha-Paul, Ronak H. Shah, James M. Cleary, David I. Quinn, Irene Brana, Victor Moreno, Mitesh J. Borad, Sherene Loi, Iben Spanggaard, James M. Ford, Daniel DiPrimeo, Michael F. Berger, Lisa DeFazio Eli, Funda Meric-Bernstam, David B. Solit, Ghassan K. Abou-Alfa
Publikováno v:
Journal of Clinical Oncology. 40:4079-4079
4079 Background: HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs) and are associated with poor overall survival (OS) in patients with metastatic disease. HER2 overexpression is associated with an increased risk of disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97d824c87fd28c270fdc6a850cf76c5c
https://doi.org/10.1200/jco.2022.40.16_suppl.4079
https://doi.org/10.1200/jco.2022.40.16_suppl.4079
Autor:
Komal L. Jhaveri, Jonathan W. Goldman, Sara A. Hurvitz, Angel Guerrero-Zotano, Nisha Unni, Adam Brufsky, Haeseong Park, James Ross Waisman, Eddy Shih-Hsin Yang, Iben Spanggaard, Sonya A. Reid, Mark E. Burkard, Aleix Prat, Sherene Loi, John Crown, Ariella Hanker, Cynthia X. Ma, Ron Bose, Lisa DeFazio Eli, Hans Wildiers
Publikováno v:
Journal of Clinical Oncology. 40:1028-1028
1028 Background: N is an oral, irreversible pan-HER TKI with activity against HER2 mutations. Genomic analyses from the SUMMIT MBC cohort following N±F suggest that resistance to N may occur via mutant allele amplification or secondary HER2 mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9df4799c5e11838e78cf04a08127af46
https://doi.org/10.1200/jco.2022.40.16_suppl.1028
https://doi.org/10.1200/jco.2022.40.16_suppl.1028
Autor:
Edith A. Perez, Lisa DeFazio-Eli, Weidong Huang, Gerald J. Wallweber, Sohail Balasubramanian, Jodi Weidler, Saranya Chumsri, Siraj M. Ali, Angela DeRidder, Ahmed Chenna, Lindsay Goicocheal
Publikováno v:
Journal of the National Comprehensive Cancer Network. 13:1066-1070
In the current genomic era, increasing evidence demonstrates that approximately 2% of HER2-negative breast cancers, by current standard testings, harbor activating mutations of ERBB2. However, whether patients with HER2-negative breast cancer with ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f91636c83d8ac88eeaae3ede19750fc1
https://doi.org/10.6004/jnccn.2015.0132
https://doi.org/10.6004/jnccn.2015.0132
Autor:
Laurie Goodman, Herjit Pannu, Jeffrey S. Larson, Lili Chen, Steve Williams, Jeff Sperinde, Ali Mukherjee, Xueguang Jin, Elicia Penuel, Sailaja Pidaparthi, John Winslow, Gerald J. Wallweber, Yuping Tan, Rajiv Dua, Lisa DeFazio-Eli, Weidong Huang, Ahmed Chenna, Jeannette M. Whitcomb, Hasan Tahir, Yining Shi, Youssouf Badal, Christos J. Petropoulos
Publikováno v:
Diagnostic Molecular Pathology. 18:11-21
The availability of drugs targeting the EGFR/HER/erbB signaling pathway has created a need for diagnostics that accurately predict treatment responses. We have developed and characterized a novel assay to provide sensitive and quantitative measures o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d9dd20169aacc5fc57db91924cab03b
https://doi.org/10.1097/pdm.0b013e31818cbdb2
https://doi.org/10.1097/pdm.0b013e31818cbdb2
Autor:
Jerry Wallweber, Carlos L. Arteaga, Carl Uli Bialucha, Cammie R. Sutton, Joan T. Garrett, Seth Ettenberg, Qing Sheng, Richard Kurupi, Lisa DeFazio-Eli, Scott Collins
We examined the effects of LJM716, an HER3 (ERBB3) neutralizing antibody that inhibits ligand-induced and ligand-independent HER3 dimerization, as a single agent and in combination with BYL719, an ATP competitive p110α-specific inhibitor, against HE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::278949ae43314740c76ccda806f3356b
https://europepmc.org/articles/PMC3790862/
https://europepmc.org/articles/PMC3790862/
Autor:
Lisa DeFazio-Eli, Weidong Huang, Amber Rivera, Gordon Parry, Linda D. B. Kiss, Lili Chen, Laurie Goodman, Jeannette M. Whitcomb, Judy Cheung, Jodi Weidler, A. Paquet, Kristi Frankson, Yining Shi, Jolly Bose, Sarah Irwin, Jeffrey S. Larson, Christos J. Petropoulos, Thomas Sherwood, John Winslow, Michael Bates, Yuping Tan, Jennifer W. Cook, Shannon Utter
Publikováno v:
Pathology Research International
Pathology Research International, Vol 2010 (2010)
Pathology Research International, Vol 2010 (2010)
We report here the results of the analytical validation of assays that measure HER2 total protein (H2T) and HER2 homodimer (H2D) expression in Formalin Fixed Paraffin Embedded (FFPE) breast cancer tumors as well as cell line controls. The assays are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d3253027626906dfd430aae748c3fe1
Autor:
Joan T. Garrett, Seth Ettenberg, Carl Uli Bialucha, Cammie R. Sutton, Lisa DeFazio-Eli, Carlos L. Arteaga, Jerry Wallweber
Publikováno v:
Cancer Research. 73:5461-5461
We hypothesized that complete inhibition of HER3 is required for the optimal action of HER2 or PI3K/Akt inhibitors against HER2+ tumors. The HER3 monoclonal antibody LJM716 (LJM) inhibits ligand-induced and ligand-independent dimerization of HER3. Tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c788663be39e25232e10e522b5101df
https://doi.org/10.1158/1538-7445.am2013-5461
https://doi.org/10.1158/1538-7445.am2013-5461
Autor:
Gordon Parry, Kristi Strommen, Laurie Goodman, Lisa DeFazio-Eli, John Winslow, Trang Dao-Pick
Publikováno v:
Breast Cancer Research : BCR
Introduction Ligand-bound and phosphorylated ErbB/HER heterodimers are potent signaling forms of this receptor family, and quantitative measurements of these active receptors may be predictive of patient response to targeted therapies. Using VeraTag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2a66e0f0e2e9c6a4429530b446d37d